Medpace Holdings, Inc. (NASDAQ:MEDP) CEO Buys $15,212,453.97 in Stock
Medpace Holdings, Inc. (NASDAQ:MEDP) CEO Buys $15,212,453.97 in Stock
Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) CEO August J. Troendle bought 94,119 shares of the stock in a transaction on Wednesday, September 21st. The stock was purchased at an average price of $161.63 per share, for a total transaction of $15,212,453.97. Following the purchase, the chief executive officer now directly owns 6,425,593 shares of the company's stock, valued at $1,038,568,596.59. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.
纳斯达克首席执行官奥古斯特·J·特伦德尔在9月21日星期三的一次交易中购买了94,119股票。股票是以每股161.63美元的平均价格购买的,总交易额为15,212,453.97美元。收购完成后,这位首席执行官现在直接拥有6425,593股公司股票,价值1,038,568,596.59美元。此次收购是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过美国证券交易委员会网站.
Medpace Stock Performance
Medace股票表现
Shares of MEDP traded down $0.95 during trading hours on Thursday, hitting $154.83. 393,461 shares of the company were exchanged, compared to its average volume of 343,725. The firm's 50 day moving average is $161.31 and its 200-day moving average is $152.71. Medpace Holdings, Inc. has a 52 week low of $126.94 and a 52 week high of $231.00. The company has a market cap of $4.80 billion, a PE ratio of 26.88 and a beta of 1.47.
在周四的交易时段,MEDP的股价下跌了0.95美元,触及154.83美元。该公司股票成交量为393,461股,而其平均成交量为343,725股。该公司的50日移动均线切入位在161.31美元,200日移动均线切入位在152.71美元。Medace Holdings,Inc.的52周低点为126.94美元,52周高位为231.00美元。该公司市值为48亿美元,市盈率为26.88倍,贝塔系数为1.47。
Medpace (NASDAQ:MEDP – Get Rating) last announced its earnings results on Monday, July 25th. The company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.12. Medpace had a return on equity of 30.56% and a net margin of 16.27%. The firm had revenue of $351.21 million during the quarter, compared to the consensus estimate of $344.01 million. During the same quarter in the prior year, the company earned $1.06 EPS. The firm's revenue for the quarter was up 26.2% compared to the same quarter last year. As a group, equities analysts forecast that Medpace Holdings, Inc. will post 6.16 earnings per share for the current fiscal year.
MedPace(纳斯达克代码:MEDP-GET Rating)上一次公布财报是在7月25日星期一。该公司公布本季度每股收益为1.46美元,比普遍预期的1.34美元高出0.12美元。Medace的股本回报率为30.56%,净利润率为16.27%。该公司本季度营收为3.5121亿美元,而市场普遍预期为3.4401亿美元。去年同期,该公司每股收益为1.06美元。该公司本季度的收入比去年同期增长了26.2%。作为一个整体,股票分析师预测Medace Holdings,Inc.本财年每股收益将达到6.16美元。
Institutional Trading of Medpace
MedPace的机构交易
Analyst Ratings Changes
分析师评级发生变化
Several research firms have recently issued reports on MEDP. StockNews.com downgraded Medpace from a "buy" rating to a "hold" rating in a research note on Thursday, September 8th. UBS Group began coverage on Medpace in a research note on Wednesday, September 7th. They set a "sell" rating and a $142.00 price target for the company.
几家研究公司最近发布了关于MEDP的报告。在9月8日周四的一份研究报告中,StockNews.com将MedPace的评级从“买入”下调至“持有”。瑞银集团于9月7日(星期三)在一份研究报告中开始对MedPace进行报道。他们为该公司设定了“卖出”评级和142.00美元的目标价。
About Medpace
关于MedPace
(Get Rating)
(获取评级)
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Medace控股公司在北美、欧洲和亚洲提供以临床研究为基础的药物和医疗器械开发服务。它在不同的治疗领域提供一整套服务,支持从第一阶段到第四阶段的临床开发过程。该公司还为制药、生物技术和医疗器械行业提供临床开发服务;开发计划设计、协调中心实验室、项目管理、法规事务、临床监测、数据管理和分析、药物警戒新药申请提交以及上市后临床支持服务。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Medpace (MEDP)
- What Steelcase's Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 免费获取StockNews.com关于MedPace的研究报告(MEDP)
- 斯蒂尔凯斯的收益说明了他重返办公室的原因吗?
- 这些机构持有达顿餐饮国际公司的股份
- 这三大股利支付者也拥有强劲的价格增长
- 住房建设的黄金时代已经结束了吗?
- 天然气价格继续回升,这些股票应该会受益
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
接受Medace Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯,接收对MedPace和相关公司的最新新闻和分析师评级的每日简要摘要。